Placement Completed
TrivarX placement
A$4.2m raised
ASX: TRI · A$0.008 cash per share · -30% premium
Advisers
TrivarX
Issuer
Not disclosed
Lead managers
- Lead manager
- Issuer
- TrivarX
- Completed
- 16 Oct 2025
- Sector
- Biotech and pharmaceuticals
Similar deals
- Neurizon Therapeutics placement Nov 2026 · A$4.3m · Biotech and pharmaceuticals
- Chimeric Therapeutics placement Dec 2025 · A$4.4m · Biotech and pharmaceuticals
- Recce Pharmaceuticals placement Jun 2026 · A$4m · Biotech and pharmaceuticals
- NeuroScientific Biopharmaceuticals placement Apr 2025 · A$3.5m · Biotech and pharmaceuticals
- Bioxyne placement Mar 2025 · A$3m · Biotech and pharmaceuticals
Sources
- 16 Oct 2025 Acquisition of Stabl-Im technology and Private Placement ASX